Key insights
- Abbott Laboratories director John Stratton purchased $173,640 in company shares, signaling insider confidence. While the company faces news regarding increased diabetic ketoacidosis hospitalizations, it also received positive regulatory nods for new diabetes monitoring sensors and AI-powered imaging software, alongside reaffirmation for its colorectal cancer screening options. These developments, coupled with an analyst price target adjustment, present a mixed but potentially stable outlook for ABT.
John G. Stratton, a director at Abbott Laboratories (NYSE:ABT), purchased common shares of the company on May 7, 2026, according to a recent SEC filing.
Mr. Stratton acquired 2,000 shares of Abbott Laboratories common stock at a price of $86.82 per share. This transaction amounted to a total value of $173,640. Following this purchase, Mr. Stratton directly holds 23,319 shares of the company’s common stock. The director’s buy comes as Abbott trades at $88.41, already above his purchase price, and remains undervalued according to InvestingPro analysis, placing it among opportunities on the Most Undervalued list. The healthcare giant has maintained dividend payments for 56 consecutive years, according to InvestingPro Tips, with a current yield of 2.85%. Investors can access Abbott’s comprehensive Pro Research Report for deeper insights into the company’s $154.2 billion market cap position.
In other recent news, Abbott Laboratories reported an increase in diabetic ketoacidosis-related hospitalizations among people with Type 1 diabetes in the United States. The data, presented at the American Diabetes Association’s 86th Scientific Sessions, indicated a 24% rise in hospitalization rates from 2017 to 2024. Furthermore, Abbott announced it has secured CE Mark approval for its Libre Duo and Libre Duo 10 Day sensors, which continuously monitor glucose and ketone levels, potentially aiding in the early detection of diabetic ketoacidosis.
Additionally, Abbott received both FDA clearance and CE Mark for its Ultreon 3.0 Software, an AI-powered imaging platform designed for coronary procedures. This technology provides real-time guidance during interventions, using optical coherence tomography to capture detailed images of coronary arteries. In another development, the American Cancer Society reaffirmed Abbott’s Cologuard and Cologuard Plus as preferred noninvasive colorectal cancer screening options for adults aged 45 and older.
Meanwhile, Leerink Partners adjusted its price target for Abbott Laboratories, lowering it to $106 from $119, while maintaining a Market Perform rating. The firm highlighted mixed first-quarter results, noting a 1% increase in worldwide sales and adjusted earnings per share that met expectations. However, it pointed out weaker-than-expected results in the company’s respiratory segment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates ABT every month against thousands of alternatives using 100+ financial metrics.It found Siemens Energy (+231.5%) and Sandisk (+189%) before the crowd did. Could ABT be next—or is there a better opportunity in the same space?Don't wait to find out.